BSE Live
Apr 08, 16:01Prev. Close
339.70
Open Price
345.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 08, 15:48Prev. Close
339.20
Open Price
345.00
Bid Price (Qty.)
345.85 (48)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of FDC (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 367.67 | 397.95 | 265.69 | 285.45 | 380.45 | |
| Net CashFlow From Operating Activities | 310.34 | 220.81 | 164.72 | 162.38 | 209.84 | |
| Net Cash Used In Investing Activities | -199.45 | -17.76 | 3.62 | -147.42 | -84.18 | |
| Net Cash Used From Financing Activities | -92.10 | -202.03 | -179.83 | -9.70 | -126.49 | |
| Foreign Exchange Gains / Losses | 0.12 | 0.01 | 0.11 | 0.15 | 0.02 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 18.90 | 1.02 | -11.38 | 5.41 | -0.80 | |
| Cash And Cash Equivalents Begin of Year | 20.77 | 19.75 | 31.13 | 25.72 | 26.52 | |
| Cash And Cash Equivalents End Of Year | 39.67 | 20.77 | 19.75 | 31.13 | 25.72 |
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth